Market Closed - Nasdaq Stockholm 07:59:43 2023-11-03 am EDT 5-day change 1st Jan Change
0.1604 SEK -1.11% Intraday chart for IRRAS AB -.--% -.--%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index CI
IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index CI
Irras Obtains Nasdaq Approval for Delisting in Stockholm MT
Sweden's Irras Files for Delisting as Privatization Nears Completion MT
Irras Obtains Extension for SEK20 Million Loan MT
Irras Shareholder Extends, Upsizes Loan MT
Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (OM : IRRAS). CI
Swedish Medical Device Company Irras Warns of Possible High Risk of Insolvency MT
IR Holding Bidco Extends Acceptance Period for Irras Takeover MT
Transcript : IRRAS AB, Q2 2023 Earnings Call, Aug 04, 2023
Irras Extends Loan Agreement with Second-biggest Shareholder MT
IRRAS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Irras' Independent Bid Panel Backs IR Holding's SEK143 Million Takeover Offer MT
Irras Surges 19% on Takeover Offer From IR Holding Bidco MT
Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited agreed to acquire IRRAS AB (OM : IRRAS) for approximately SEK 140 million. CI
IRRAS AB Provides Sales Guidance for the Second Quarter of 2024 CI
IRRAS AB Shifts Commercial Strategy to Focus Resources on United States Market Opportunity CI
IRRAS AB Announces Resignation of Eva Nilsagård as a Board Member CI
Transcript : IRRAS AB, Q1 2023 Earnings Call, May 17, 2023
IRRAS AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
IRRAS AB Auditor Raises 'Going Concern' Doubt CI
Transcript : IRRAS AB, Q4 2022 Earnings Call, Feb 16, 2023
IRRAS AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
IRRAS AB Announces That the Publication of the First Comparative Study CI
IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit CI
Chart IRRAS AB
More charts
Irras AB is a Sweden-based medical technology company. It offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company’s shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. IRRAS Stock
  4. News IRRAS AB
  5. Irras Obtains Nasdaq Approval for Delisting in Stockholm